Weekly low‐dose versus three‐weekly high‐dose cisplatin for concurrent chemoradiation in locoregionally advanced non‐nasopharyngeal head and neck cancer: a …
Background Three‐weekly high‐dose cisplatin (100 mg/m2) is considered the standard
systemic regimen given concurrently with postoperative or definitive radiotherapy in locally …
systemic regimen given concurrently with postoperative or definitive radiotherapy in locally …
Low-dose vs. high-dose cisplatin: lessons learned from 59 chemoradiotherapy trials in head and neck cancer
In locally advanced squamous cell carcinomas of the head and neck (LA-SCCHN),
concurrent chemoradiotherapy is an integral part of multimodality management both in the …
concurrent chemoradiotherapy is an integral part of multimodality management both in the …
Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): a multicenter, noninferiority, phase II/III randomized controlled trial
N Kiyota, M Tahara, J Mizusawa, T Kodaira… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE The standard treatment for postoperative high-risk locally advanced squamous
cell carcinoma of the head and neck (LA-SCCHN) is chemoradiotherapy with 3-weekly …
cell carcinoma of the head and neck (LA-SCCHN) is chemoradiotherapy with 3-weekly …
Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial
Purpose Chemoradiation with cisplatin 100 mg/m2 given once every 3 weeks is the
standard of care in locally advanced head and neck squamous cell cancer (LAHNSCC) …
standard of care in locally advanced head and neck squamous cell cancer (LAHNSCC) …
Cisplatin eligibility issues and alternative regimens in locoregionally advanced head and neck cancer: recommendations for clinical practice
P Szturz, V Cristina, RG Herrera Gómez… - Frontiers in …, 2019 - frontiersin.org
Well-designed randomized trials provide the highest level of scientific evidence to guide
clinical decision making. In chemoradiotherapy of locally advanced squamous cell …
clinical decision making. In chemoradiotherapy of locally advanced squamous cell …
Disease‐induced and treatment‐induced alterations in body composition in locally advanced head and neck squamous cell carcinoma
ACH Willemsen, A Hoeben, RI Lalisang… - Journal of cachexia …, 2020 - Wiley Online Library
Background Chemoradiation or bioradiation treatment (CRT/BRT) of locally advanced head
and neck squamous cell carcinoma (LAHNSCC) comes with high toxicity rates, often leading …
and neck squamous cell carcinoma (LAHNSCC) comes with high toxicity rates, often leading …
[HTML][HTML] Impact of cisplatin dose intensity on human papillomavirus-related and-unrelated locally advanced head and neck squamous cell carcinoma
Aim The aim is to evaluate the impact of cisplatin dose modification on outcomes of human
papillomavirus (HPV)-related (HPV+) and HPV-unrelated (HPV−) locally advanced head …
papillomavirus (HPV)-related (HPV+) and HPV-unrelated (HPV−) locally advanced head …
[HTML][HTML] Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer
RH de Roest, M van der Heijden… - Radiotherapy and …, 2022 - Elsevier
Background Definitive concomitant cisplatin-based chemoradiotherapy (CRT) is the current
gold standard for most patients with advanced stage head and neck squamous cell …
gold standard for most patients with advanced stage head and neck squamous cell …
A pilot study of a smartphone-based monitoring intervention on head and neck cancer patients undergoing concurrent chemo-radiotherapy
Background Multidisciplinary treatment for head and neck carcinoma offers the best curative
results but generates acute toxicities, which negatively affect both patients' quality of life and …
results but generates acute toxicities, which negatively affect both patients' quality of life and …
Electrospun nanofibers for local anticancer therapy: Review of in vivo activity
L Poláková, J Širc, R Hobzová, AI Cocârță… - International journal of …, 2019 - Elsevier
Currently, chemotherapy is the most common treatment for oncological diseases. Systemic
administration of chemotherapeutics provides an easy and effective distribution of the active …
administration of chemotherapeutics provides an easy and effective distribution of the active …